Search for other works by this author on: ...

1Seoul National University, Seoul, Korea, Republic of.

Cancer Immunotherapies (CITs) have shown unprecedented results in improving tumor control. However, many patients are still refractory to treatment. A deeper understanding of CIT-drugs mode of action ...

The NIH recently announced a cap of 15% on indirect costs for new grants. This plan has been temporarily blocked in federal court with a hearing scheduled for February 21. If cuts are implemented, ...

Immune checkpoint blockade (ICB) therapy has revolutionized cancer treatment, delivering impressive results across various cancers. However, resistance is common, and only a limited number of patients ...

Research shows that chimeric antigen receptor (CAR) T cells can endow other immune cells with their cancer-killing abilities through trogocytosis, the exchange of cell-surface proteins with ...

A Centers for Disease Control and Prevention (CDC) meeting on vaccines originally scheduled for next week has been postponed, according to a senior official from the Department of Health and Human ...

A woman who received chimeric antigen receptor (CAR) T-cell therapy for neuroblastoma as a girl in 2006 is in complete remission more than 18 years later, according to a long-term follow up report ...

Major Finding: Myeloid-derived suppressor cells (MDSC) crosstalk with IDH–wild-type glioblastoma and promote tumor growth. Concept: Signaling between MDSCs and tumor cells support cell survival in ...

Fred Hutch Cancer Center in Seattle, WA, terminated its diversity, equity, and inclusion (DEI) initiatives due to President Donald Trump’s executive order threatening to withhold funding to federal ...

The HER2×HER3 bispecific antibody zenocutuzumab demonstrated efficacy in treating rare cancers driven by NRG1 fusions, leading to its accelerated approval for certain pancreatic and lung cancers.

Copyright held by the owner/author(s).